Every new orthopedic 510(k) clearance, filtered for what's clinically or competitively significant. Not the commodity filings — the ones that matter.
🧪
In the Pipeline
New clinical trials worth watching — with context on what the results could mean for surgical practice and market share when they land.
📄
From the Literature
Peer-reviewed research with real-world implications. Translated from academic to actionable — what surgeons and reps actually need to know.
📰
Market Moves
Funding rounds, acquisitions, partnerships, and launches. The signals that tell you where money and attention are flowing before everyone else knows.
Sample Issue
What a typical edition looks like
The Preference Card
Orthopedic Industry Intelligence
Week of June 9, 2025 · Edition #12
🔬 FDA Watch
Persona IQ Smart Knee System (Zimmer Biomet, K243021)— First FDA-cleared implant with embedded motion sensors; changes the post-op data conversation with patients and payors.
Tigon Surgical ARIA Robotic System (K250188)— Smaller footprint than Mako; targets ASC market where OR space is a real constraint.
🧪 In the Pipeline
BEAR Implant vs. ACL Reconstruction (NCT05902442, Phase III)— Biodesign Medical's bridge repair tech just moved to its pivotal trial; a positive outcome rewrites the ACL standard of care.
📄 From the Literature
"Robotic-assisted TKA achieves superior limb alignment vs. conventional" — JBJS, Smith et al.— Alignment accuracy improved 34%; the data hospitals will cite when justifying robot capex.
📰 Market Moves
Stryker acquires Artelon for $280M— Soft-tissue augmentation play; fills a gap in their biologics portfolio that's been visible since the Bioness deal.
About
Built in the field. Written for it.
"I spent years in Minnesota ORs as an Arthrex rep. I know what a scrub tech needs to hear at 6am and what a surgeon actually wants to know about a new clearance. This is that newsletter."
The Preference Card is written by a former orthopedic device sales professional with direct surgical coverage experience. Every edition is synthesized from primary sources — FDA databases, ClinicalTrials.gov, PubMed, and industry feeds — not press releases.
It's built for people who are in the room where the decisions get made: surgeons choosing implants, reps defending their portfolio, administrators evaluating capital equipment, and investors tracking where the market is heading.